Display options
Share it on

Evid Based Complement Alternat Med. 2014;2014:651053. doi: 10.1155/2014/651053. Epub 2014 Apr 30.

Effect of Eclipta prostrata on 11Beta-Hydroxysteroid Dehydrogenase in Rat Liver and Kidney.

Evidence-based complementary and alternative medicine : eCAM

Chenshu Xu, Binghua Wei, Xiaohua Fu, Meijuan Luo, Shidai Liu, Ruiming Li, Bin Ren, Lei Tang

Affiliations

  1. Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan No. 2 Road, Guangzhou, Guangdong 510080, China.
  2. Department of Pharmacy, Guangzhou Xinhai Hospital, Guangzhou, Guangdong 510300, China.

PMID: 24876875 PMCID: PMC4021844 DOI: 10.1155/2014/651053

Abstract

Eclipta prostrata (EP) is often prescribed in combination with glucocorticoid to treat glomerular nephritis, nephrotic syndrome, and IgA nephropathy in clinical practice of Traditional Chinese Medicine. Previous studies from our laboratory revealed that coadministration of EP significantly increased the plasma concentration of prednisolone while decreased the level of cotreated prednisone in rats. However, the underlying mechanism remains unclear. 11 β -Hydroxysteroid dehydrogenase (11 β -HSD) belongs to the family of oxidoreductases that catalyze the interconversion of prednisone to active prednisolone. Therefore, the current study aimed to investigate the effects of EP on the activity and expression of 11 β -HSD in rat liver and kidney. The results showed that oral administration of EP significantly increased the activity of 11 β -HSD I in the liver and 11 β -HSD II in the kidney by employing the microsomal incubation system. Moreover, gene and protein expressions of 11 β -HSD I and 11 β -HSD II were also increased in rat liver and kidney, respectively. These results suggest that the effects of EP on 11 β -HSD may attribute to the mechanism that administration of EP improves the efficacy and reduces adverse drug reactions of glucocorticoid in patients undergoing combinational therapy.

References

  1. J Steroid Biochem Mol Biol. 2010 Mar;119(1-2):1-13 - PubMed
  2. J Steroid Biochem Mol Biol. 2010 Mar;119(1-2):56-72 - PubMed
  3. Endocr Connect. 2013 Jun 14;2(3):125-136 - PubMed
  4. J Chromatogr. 1982 Apr 30;239:711-6 - PubMed
  5. Br J Clin Pharmacol. 1989 Oct;28(4):373-87 - PubMed
  6. J Clin Endocrinol Metab. 2007 Mar;92(3):857-64 - PubMed
  7. N Engl J Med. 2005 Oct 20;353(16):1711-23 - PubMed
  8. J Clin Endocrinol Metab. 2008 Feb;93(2):550-6 - PubMed
  9. Drug Metab Dispos. 2009 Jul;37(7):1539-47 - PubMed
  10. Phytother Res. 2011 Sep;25(9):1313-6 - PubMed
  11. Nutr Res. 2010 Aug;30(8):579-84 - PubMed
  12. Biochim Biophys Acta. 2011 Oct;1813(10):1814-21 - PubMed
  13. Br Med J (Clin Res Ed). 1983 Mar 19;286(6369):923-5 - PubMed
  14. Planta Med. 2013 Aug;79(12):1031-7 - PubMed
  15. Mol Cell Endocrinol. 2012 Mar 24;350(2):168-86 - PubMed
  16. Life Sci. 2006 May 15;78(25):2931-6 - PubMed
  17. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):229-34 - PubMed
  18. Biochem Pharmacol. 1994 May 18;47(10):1805-12 - PubMed
  19. Food Chem Toxicol. 2012 Nov;50(11):4016-22 - PubMed
  20. Endocrinology. 2001 Apr;142(4):1371-6 - PubMed
  21. Physiol Rev. 2013 Jul;93(3):1139-206 - PubMed
  22. Nephrol Dial Transplant. 2002 May;17(5):753-8 - PubMed
  23. Horm Metab Res. 2011 Apr;43(4):257-60 - PubMed
  24. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 24;839(1-2):54-61 - PubMed
  25. Inflamm Bowel Dis. 2004 Sep;10(5):578-83 - PubMed
  26. Rheumatology (Oxford). 2010 Nov;49(11):2016-23 - PubMed
  27. Int J Pharm. 2010 Mar 15;387(1-2):1-6 - PubMed

Publication Types